Anti-obesity jabs like Ozempic could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug.     Researchers found after three years of treatment participants had a 20% lower risk of obesity and its associated health impacts, which currently cost the NHS over £6bn per year.    On the Sky News Daily, Niall Paterson speaks to Sky’s science and medical correspondent Thomas Moore about the implications of reducing heart disease cases for the NHS, and senior lecturer in physiology at Anglia Ruskin University Dr Simon Clarke explains how the wonder-drug actually works.      Producer: Emma Rae Woodhouse Podcast Promotions Producer: David Chipakupaku   Editor: Philly Beaumont